REG - Feedback PLC - Partnership with Amazon Web Services

FeedbackAnnouncement

13/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211213:nRSM3521Va&default-theme=true

RNS Number : 3521V  Feedback PLC  13 December 2021

Prior to publication, the information contained within this announcement was
deemed by the Company to constitute inside information as stipulated under the
Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of
this announcement, this information is now considered to be in the public
domain.

 

Feedback plc

 

Feedback receives funding from Amazon Web Services in support of its
cloud-based tuberculosis screening programme for rural communities in India

 

·     AWS provides non-equity funding to support the initial hosting
costs of a pilot for Feedback's cloud-based tuberculosis ("TB") screening
solution to rural communities in India

·     The TB screening solution will see X-ray images acquired in rural
communities pushed by Feedback's Bleepa Box straight to the cloud to be
processed by clinical and artificial intelligence ("AI") partners

·     The TB screening pathway, hosted on Bleepa, will connect remote
communities with clinical experts and the latest technologies for point of
care diagnosis of TB in almost any setting and will be hosted on AWS Cloud

 

London, 13 December 2021: Feedback plc (AIM: FDBK, "Feedback" or the
"Company"), the specialist clinical communication company, announces that it
has partnered with Amazon Web Services (AWS) to establish and deliver
cloud-based TB screening services to rural communities in India.

 

Feedback has been awarded funding through the AWS Diagnostic Development
Initiative
(https://aws.amazon.com/government-education/nonprofits/disaster-response/diagnostic-dev-initiative/)
to deliver a revolutionary imaging pathway that will enable X-rays of patients
to be acquired in rural settings without networked connectivity and be
transmitted over Bleepa's cloud-hosted infrastructure for reporting. This
pathway will enable TB screening to be undertaken in even the most remote
setting, ensuring diagnostic input is rapidly available to screening services
whilst the patient is still in the X-ray clinic. This rapid, point-of-care
diagnostic service leverages the power of cloud to ensure that TB screening
can be scaled to rural locations across India.

 

The AWS Diagnostics Development Initiative aims to help accelerate research
and innovation to advance the collective understanding and detection of
infectious diseases in order to mitigate current and future outbreaks. The
funding is targeted at covering the initial cloud hosting costs of the TB
screening service in the pilot stages, ahead of plans to scale the service
across India following a successful pilot.

 

TB represents a large public health issue globally with India experiencing an
estimated 2.6m new cases every year. A robust screening programme, delivered
locally to citizens is essential in order to identify those affected and
initiate treatment for the condition. Chest X-rays are a key screening
investigation for TB but require interpretation by either a specialist
clinician or suitably regulated AI technology, neither of which are available
in most rural settings.

 

Feedback's technology enables a chest X-ray image to be pushed over a mobile
network to the cloud where it is shared by Bleepa either with a specialist
clinician for reporting or a suitable AI tool, the results then being shared
through Bleepa with the TB screening service, often within minutes of an image
being acquired. Specialist TB clinicians can then advise on management, using
Bleepa's patient-specific chat feature to connect directly to TB screening
personnel in order to initiate treatment whilst the patient is still in the
vicinity. The image and any clinical reports or discussion will then be stored
in a CareLocker - a cloud container that stores medical data at an individual
patient level - for every patient, which could enable the creation of citizen
health records in line with the National Digital Health Mission record
("NDHM") of the Indian government. The entire solution will be hosted on AWS
cloud.

 

Dr Tom Oakley, CEO of Feedback, said: "We are delighted to have AWS as a
partner in our TB screening programme. This funding support will enable us to
establish and subsequently scale the TB screening solution to citizens in
rural locations across India. It is a key public health priority and a
challenge of enormous proportions. To have AWS support and backing will make
all the difference in getting this out to the citizens who need it."

 

"Cloud-powered diagnostic tools are critical in the fight against
turberculosis and other infectious diseases said Maggie Carter, Global Lead,
Social Impact at AWS. "Over the last year, AWS has seen inspirational results
from the Diagnostic Development Initiative. We look forward to helping Bleepa
and other organizations worldwide use the cloud to mitigate current and future
infectious disease outbreaks."

 

Further information on Bleepa can be found on the Company's website:
https://fbkmed.com/feedback-plc/reports-and-presentations/
(https://fbkmed.com/feedback-plc/reports-and-presentations/)

 

-Ends-

 

Enquiries:

 

 Feedback plc                                    +44 (0)1954 718072

 Tom Oakley, CEO                                 IR@fbk.com (mailto:IR@fbk.com)

 Anesh Patel, CFO

 Panmure Gordon (UK) Limited (NOMAD and Broker)  +44 (0)20 7886 2500

 Emma Earl/Freddy Crossley (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Walbrook PR Ltd                                 Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
                                                 (mailto:feedbackplc@walbrookpr.com)
 Paul McManus/Nick Rome/Nicholas Johnson         07980 541 893 or 07748 325 236 or 07884 664 686

 

Notes to Editors

 

Feedback plc (AIM: FDBK) is a pioneer of regulated clinical communication
products. Its core product, Bleepa, is a revolutionary medical imaging
communications app, providing an easy-to-use, high quality tool to enable
remote and secure communications between front-line clinicians and teams.
Importantly, it is the only CE marked medical imaging communications platform
on the NHSx clinical communications tools framework. Bleepa has unparalleled
functionality for everyday practice and can be accessed from any
internet-connected device, enabling control of patient cases when on the go.

 

Its highly scalable Software as a Service ("SaaS") based revenue model will
provide increasing levels of visibility as the Company grows its customer
base. With a growing distribution base and technology in place, the focus is
on leveraging key relationships in order to drive sales both in the UK and
internationally to all forms of care providers. As a fully certified medical
device, Bleepa aims to disrupt the medical imaging communications market and,
importantly, increase the accuracy and speed of clinical review.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAEAEFLFFFAA